Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 49

1.

Making sense of Cbp/p300 loss of function mutations in skin tumorigenesis.

Anastasi S, Alemà S, Segatto O.

J Pathol. 2019 Aug 9. doi: 10.1002/path.5336. [Epub ahead of print]

PMID:
31397888
2.

Signalling networks in cholangiocarcinoma: Molecular pathogenesis, targeted therapies and drug resistance.

Fouassier L, Marzioni M, Afonso MB, Dooley S, Gaston K, Giannelli G, Rodrigues CMP, Lozano E, Mancarella S, Segatto O, Vaquero J, Marin JJG, Coulouarn C.

Liver Int. 2019 May;39 Suppl 1:43-62. doi: 10.1111/liv.14102. Review.

PMID:
30903728
3.

HSP90 Inhibition Drives Degradation of FGFR2 Fusion Proteins: Implications for Treatment of Cholangiocarcinoma.

Lamberti D, Cristinziano G, Porru M, Leonetti C, Egan JB, Shi CX, Buglioni S, Amoreo CA, Castellani L, Borad MJ, Alemà S, Anastasi S, Segatto O.

Hepatology. 2019 Jan;69(1):131-142. doi: 10.1002/hep.30127. Epub 2018 Dec 14. Erratum in: Hepatology. 2019 Feb;69(2):925.

PMID:
30067876
4.

miR-205 mediates adaptive resistance to MET inhibition via ERRFI1 targeting and raised EGFR signaling.

Migliore C, Morando E, Ghiso E, Anastasi S, Leoni VP, Apicella M, Cora' D, Sapino A, Pietrantonio F, De Braud F, Columbano A, Segatto O, Giordano S.

EMBO Mol Med. 2018 Sep;10(9). pii: e8746. doi: 10.15252/emmm.201708746.

5.

Lack of Evidence that CYTH2/ARNO Functions as a Direct Intracellular EGFR Activator.

Anastasi S, Zhu SJ, Ballarò C, Manca S, Lamberti D, Wang LJ, Alemà S, Yun CH, Segatto O.

Cell. 2016 May 19;165(5):1031-1034. doi: 10.1016/j.cell.2016.05.009. No abstract available.

6.

Regulation of the ErbB network by the MIG6 feedback loop in physiology, tumor suppression and responses to oncogene-targeted therapeutics.

Anastasi S, Lamberti D, Alemà S, Segatto O.

Semin Cell Dev Biol. 2016 Feb;50:115-24. doi: 10.1016/j.semcdb.2015.10.001. Epub 2015 Oct 9. Review.

PMID:
26456277
7.

Epigenetic silencing of miR-145-5p contributes to brain metastasis.

Donzelli S, Mori F, Bellissimo T, Sacconi A, Casini B, Frixa T, Roscilli G, Aurisicchio L, Facciolo F, Pompili A, Carosi MA, Pescarmona E, Segatto O, Pond G, Muti P, Telera S, Strano S, Yarden Y, Blandino G.

Oncotarget. 2015 Nov 3;6(34):35183-201. doi: 10.18632/oncotarget.5930.

8.

Mitogen-Inducible Gene-6 Mediates Feedback Inhibition from Mutated BRAF towards the Epidermal Growth Factor Receptor and Thereby Limits Malignant Transformation.

Milewska M, Romano D, Herrero A, Guerriero ML, Birtwistle M, Quehenberger F, Hatzl S, Kholodenko BN, Segatto O, Kolch W, Zebisch A.

PLoS One. 2015 Jun 12;10(6):e0129859. doi: 10.1371/journal.pone.0129859. eCollection 2015.

9.

Therapeutic targeting of ERBB2 in breast cancer: understanding resistance in the laboratory and combating it in the clinic.

Fabi A, Mottolese M, Segatto O.

J Mol Med (Berl). 2014 Jul;92(7):681-95. doi: 10.1007/s00109-014-1169-7. Epub 2014 May 28. Review.

PMID:
24861025
10.

A pervasive role for MIG6 in restraining cell proliferation.

Anastasi S, Castellani L, Alemà S, Segatto O.

Cell Death Differ. 2014 Mar;21(3):345-7. doi: 10.1038/cdd.2013.182. Epub 2013 Dec 20. No abstract available.

11.

Regulation of epidermal growth factor receptor signalling by inducible feedback inhibitors.

Segatto O, Anastasi S, Alemà S.

J Cell Sci. 2011 Jun 1;124(Pt 11):1785-93. doi: 10.1242/jcs.083303. Review.

12.

A two-tiered mechanism of EGFR inhibition by RALT/MIG6 via kinase suppression and receptor degradation.

Frosi Y, Anastasi S, Ballarò C, Varsano G, Castellani L, Maspero E, Polo S, Alemà S, Segatto O.

J Cell Biol. 2010 May 3;189(3):557-71. doi: 10.1083/jcb.201002032. Epub 2010 Apr 26.

13.

Mig-6 controls EGFR trafficking and suppresses gliomagenesis.

Ying H, Zheng H, Scott K, Wiedemeyer R, Yan H, Lim C, Huang J, Dhakal S, Ivanova E, Xiao Y, Zhang H, Hu J, Stommel JM, Lee MA, Chen AJ, Paik JH, Segatto O, Brennan C, Elferink LA, Wang YA, Chin L, DePinho RA.

Proc Natl Acad Sci U S A. 2010 Apr 13;107(15):6912-7. doi: 10.1073/pnas.0914930107. Epub 2010 Mar 29.

14.

The evolutionarily conserved EBR module of RALT/MIG6 mediates suppression of the EGFR catalytic activity.

Anastasi S, Baietti MF, Frosi Y, Alemà S, Segatto O.

Oncogene. 2007 Dec 13;26(57):7833-46. Epub 2007 Jun 18.

PMID:
17599051
15.

Targeted expression of RALT in mouse skin inhibits epidermal growth factor receptor signalling and generates a Waved-like phenotype.

Ballarò C, Ceccarelli S, Tiveron C, Tatangelo L, Salvatore AM, Segatto O, Alemà S.

EMBO Rep. 2005 Aug;6(8):755-61.

16.

Loss of RALT/MIG-6 expression in ERBB2-amplified breast carcinomas enhances ErbB-2 oncogenic potency and favors resistance to Herceptin.

Anastasi S, Sala G, Huiping C, Caprini E, Russo G, Iacovelli S, Lucini F, Ingvarsson S, Segatto O.

Oncogene. 2005 Jun 30;24(28):4540-8.

PMID:
15856022
17.

Constitutively active Notch1 induces growth arrest of HPV-positive cervical cancer cells via separate signaling pathways.

Talora C, Cialfi S, Segatto O, Morrone S, Kim Choi J, Frati L, Paolo Dotto G, Gulino A, Screpanti I.

Exp Cell Res. 2005 May 1;305(2):343-54.

PMID:
15817159
18.

Feedback inhibition by RALT controls signal output by the ErbB network.

Anastasi S, Fiorentino L, Fiorini M, Fraioli R, Sala G, Castellani L, Alemà S, Alimandi M, Segatto O.

Oncogene. 2003 Jul 3;22(27):4221-34.

PMID:
12833145
19.

Expression of RALT, a feedback inhibitor of ErbB receptors, is subjected to an integrated transcriptional and post-translational control.

Fiorini M, Ballarò C, Sala G, Falcone G, Alemà S, Segatto O.

Oncogene. 2002 Sep 19;21(42):6530-9.

20.

Negative regulation of receptor tyrosine kinase signals.

Fiorini M, Alimandi M, Fiorentino L, Sala G, Segatto O.

FEBS Lett. 2001 Feb 16;490(3):132-41. Review.

21.

Inhibition of ErbB-2 mitogenic and transforming activity by RALT, a mitogen-induced signal transducer which binds to the ErbB-2 kinase domain.

Fiorentino L, Pertica C, Fiorini M, Talora C, Crescenzi M, Castellani L, Alemà S, Benedetti P, Segatto O.

Mol Cell Biol. 2000 Oct;20(20):7735-50.

22.

Analysis of protein-protein interactions involved in the activation of the Shc/Grb-2 pathway by the ErbB-2 kinase.

Ricci A, Lanfrancone L, Chiari R, Belardo G, Pertica C, Natali PG, Pelicci PG, Segatto O.

Oncogene. 1995 Oct 19;11(8):1519-29.

PMID:
7478576
23.

Constitutive phosphorylation of Shc proteins in human tumors.

Pelicci G, Lanfrancone L, Salcini AE, Romano A, Mele S, Grazia Borrello M, Segatto O, Di Fiore PP, Pelicci PG.

Oncogene. 1995 Sep 7;11(5):899-907.

PMID:
7675449
24.

Expression of gp185HER-2 in human cutaneous melanoma: implications for experimental immunotherapeutics.

Natali PG, Nicotra MR, Digiesi G, Cavaliere R, Bigotti A, Trizio D, Segatto O.

Int J Cancer. 1994 Feb 1;56(3):341-6.

PMID:
7906252
25.

Shc products are substrates of erbB-2 kinase.

Segatto O, Pelicci G, Giuli S, Digiesi G, Di Fiore PP, McGlade J, Pawson T, Pelicci PG.

Oncogene. 1993 Aug;8(8):2105-12.

PMID:
8101647
26.
27.

Changes in expression of alpha 6/beta 4 integrin heterodimer in primary and metastatic breast cancer.

Natali PG, Nicotra MR, Botti C, Mottolese M, Bigotti A, Segatto O.

Br J Cancer. 1992 Aug;66(2):318-22.

28.

Production and characterization of murine mAbs to the extracellular domain of human neu oncogene product GP185HER2.

Digiesi G, Giacomini P, Fraioli R, Mariani M, Nicotra MR, Segatto O, Natali PG.

Hybridoma. 1992 Aug;11(4):519-27.

PMID:
1383128
29.

erbB-2 autophosphorylation is required for mitogenic action and high-affinity substrate coupling.

Segatto O, Lonardo F, Helin K, Wexler D, Fazioli F, Rhee SG, Di Fiore PP.

Oncogene. 1992 Jul;7(7):1339-46.

PMID:
1352397
30.

Identification and biochemical characterization of novel putative substrates for the epidermal growth factor receptor kinase.

Fazioli F, Bottaro DP, Minichiello L, Auricchio A, Wong WT, Segatto O, Di Fiore PP.

J Biol Chem. 1992 Mar 15;267(8):5155-61.

31.

The juxtamembrane regions of the epidermal growth factor receptor and gp185erbB-2 determine the specificity of signal transduction.

Segatto O, Lonardo F, Wexler D, Fazioli F, Pierce JH, Bottaro DP, White MF, Di Fiore PP.

Mol Cell Biol. 1991 Jun;11(6):3191-202.

32.
33.

Cloning, expression, and biological effects of erbB-2/neu gene in mammalian cells.

Di Fiore PP, Segatto O, Aaronson SA.

Methods Enzymol. 1991;198:272-7. No abstract available.

PMID:
1677443
34.

The normal erbB-2 product is an atypical receptor-like tyrosine kinase with constitutive activity in the absence of ligand.

Lonardo F, Di Marco E, King CR, Pierce JH, Segatto O, Aaronson SA, Di Fiore PP.

New Biol. 1990 Nov;2(11):992-1003.

PMID:
1983208
35.
36.

EGF receptor and erbB-2 tyrosine kinase domains confer cell specificity for mitogenic signaling.

Di Fiore PP, Segatto O, Taylor WG, Aaronson SA, Pierce JH.

Science. 1990 Apr 6;248(4951):79-83.

PMID:
2181668
37.

The role of autophosphorylation in modulation of erbB-2 transforming function.

Segatto O, Lonardo F, Pierce JH, Bottaro DP, Di Fiore PP.

New Biol. 1990 Feb;2(2):187-95.

PMID:
1982072
38.

Analysis of the antigenic profile of uveal melanoma lesions with anti-cutaneous melanoma-associated antigen and anti-HLA monoclonal antibodies.

Natali PG, Bigotti A, Nicotra MR, Nardi RM, Delovu A, Segatto O, Ferrone S.

Cancer Res. 1989 Mar 1;49(5):1269-74.

39.

Different structural alterations upregulate in vitro tyrosine kinase activity and transforming potency of the erbB-2 gene.

Segatto O, King CR, Pierce JH, Di Fiore PP, Aaronson SA.

Mol Cell Biol. 1988 Dec;8(12):5570-4.

40.

erbB-2 is a potent oncogene when overexpressed in NIH/3T3 cells.

Di Fiore PP, Pierce JH, Kraus MH, Segatto O, King CR, Aaronson SA.

Science. 1987 Jul 10;237(4811):178-82.

PMID:
2885917
41.

Multiple epitope recognition: an approach to improved radioimmunodetection of tumor-associated antigens.

Giacomini P, Segatto O, Natali PG.

Int J Cancer. 1987 Jun 15;39(6):729-36.

PMID:
2438235
42.

The human transforming growth factor type alpha coding sequence is not a direct-acting oncogene when overexpressed in NIH 3T3 cells.

Finzi E, Fleming T, Segatto O, Pennington CY, Bringman TS, Derynck R, Aaronson SA.

Proc Natl Acad Sci U S A. 1987 Jun;84(11):3733-7.

43.

Analysis with monoclonal antibodies of the molecular and cellular heterogeneity of human high molecular weight melanoma associated antigen.

Ziai MR, Imberti L, Nicotra MR, Badaracco G, Segatto O, Natali PG, Ferrone S.

Cancer Res. 1987 May 1;47(9):2474-80.

44.

Clinical improvement and partial correction of the T cell defects of acquired immunodeficiency syndrome (AIDS) and lymphoadenopathy syndrome (LAS) by a calf thymus acid lysate.

Valesini G, Barnaba V, Levrero M, Balsano F, Segatto O, Natali PG.

Eur J Cancer Clin Oncol. 1986 Apr;22(4):531-2. No abstract available.

PMID:
3488221
45.

Role of genes for normal growth factors in human malignancy.

Aaronson SA, Igarashi H, Rao CD, Finzi E, Fleming TP, Segatto O, Robbins KC.

Princess Takamatsu Symp. 1986;17:95-108. Review.

PMID:
3332023
46.

Thy 1.2 antigen inducing capacity of a calf thymus acid hydrolysate and its fractions.

Segatto O, Secchi C, Berrini A, Natali PG.

Int J Tissue React. 1986;8(3):225-9.

PMID:
2877957
47.

Lymphoid stroma of Warthin's tumor: phenotypic analogies with gut-associated lymphoid tissue.

Segatto O, Giacomini P, Santoro L, Perrino A, Natali PG.

Clin Immunol Immunopathol. 1985 Jan;34(1):39-47.

PMID:
3880683
48.

Differential tissue distribution and ontogeny of DC-1 and HLA-DR antigens.

Natali PG, Segatto O, Ferrone S, Tosi R, Corte G.

Immunogenetics. 1984;19(2):109-16.

PMID:
6421723
49.

Isolation of viable melanoma cells from surgically removed lesions using dishes coated with monoclonal antibody to a high molecular weight melanoma associated antigen.

Natali PG, Segatto O, Zupi G, Cavaliere R, Giacomini P, Ferrone S.

J Immunol Methods. 1983 Sep 16;62(3):337-46.

PMID:
6886437

Supplemental Content

Loading ...
Support Center